Display Settings:

Format

Send to:

Choose Destination
See comment in PubMed Commons below
Curr Drug Deliv. 2005 Oct;2(4):383-93.

Lipid-based self-adjuvanting vaccines.

Author information

  • 1The Cooperative Research Centre for Vaccine Technology, The Department of Microbiology and Immunology, The University of Melbourne, Parkville, Victoria, Australia 3010. l.brown@microbiology.unimelb.edu.au

Abstract

Lipopeptides incorporating epitopes for CD4+ T cells and either CD8+ T cells or B cells have proven to be immunogenic in animal models and in humans and are well tolerated in these species. This form of vaccine candidate has great benefits over competing technology in terms of providing a totally synthetic and pure product that is effective when administered in the absence of any adjuvant, and is immunogenic when delivered by a variety of routes, including application to mucosal surfaces. The immune response can be focused on critical epitopes of the pathogen or tumour antigen to provide clearing immunity, and responses can also be invoked that modulate hormone activity. This review will cover examples of lipopeptides of different design and their efficacy in different systems as well as challenges for the future. Our recent understanding of how the lipid component confers the "self-adjuvanting" property on these immunogens by targeting the cell at the heart of immune response induction, the dendritic cell, will also be discussed.

PMID:
16305441
[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Bentham Science Publishers Ltd.
    Loading ...
    Write to the Help Desk